Oxa Spiro Derivatives Bias MOR Signaling to Reduce Side Effects
Solution Overview
Problem
Current opioid drugs for pain management suffer from side effects such as tolerance and respiratory depression due to their interaction with the β-arrestin pathway, leading to reduced therapeutic efficacy and increased risk of receptor desensitization.
Innovation Solution
Development of oxo spiro derivatives that act as selective MOR agonists with enhanced activity by cyclizing the benzylic position, improving selectivity and reducing β-arrestin-mediated side effects through a specific pharmaceutical composition and preparation method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional opioid drugs are used to achieve analgesic effects through MOR receptor activation, then pain relief is provided, but side effects such as tolerance and respiratory depression occur due to β-arrestin pathway activation
Solution Approach 1:
The patent segments the signaling pathway activation by designing ligands that selectively activate the G protein pathway while avoiding β-arrestin pathway activation. This is achieved through specific molecular structures (oxa spiro derivatives with particular substituent patterns) that create a bias toward G protein coupling, thereby separating the analgesic effect from the harmful side effects mediated by β-arrestin
Solution Approach 2:
The patent changes the chemical parameters of the opioid ligands by introducing specific structural modifications to the aza spiro core structure, including varying substituents at positions R1, R2, R3, and the aromatic ring systems. These parameter changes result in ligands with altered binding characteristics that favor G protein activation over β-arrestin recruitment, thereby improving the therapeutic profile
2Duration of action of moving object
If opioid drugs activate both G protein and β-arrestin pathways to produce analgesic effects, then pain relief is achieved, but receptor desensitization occurs leading to tolerance
Solution Approach 1:
The patent extracts the harmful β-arrestin pathway activation from the overall signaling response by designing ligands that are biased toward G protein coupling. The molecular structures are optimized to minimize β-arrestin recruitment while maintaining strong MOR receptor activation, thereby prolonging the duration of analgesic effect without inducing receptor desensitization and tolerance
Solution Approach 2:
The patent introduces dynamic selectivity in pathway activation by creating ligands that can adaptively favor G protein signaling. The oxa spiro derivatives with specific substituent configurations exhibit dynamic binding characteristics that promote sustained G protein activation while avoiding the static desensitization mechanism triggered by β-arrestin, thereby maintaining receptor sensitivity over time
3Reliability
If morphine is used to activate MOR receptor, then analgesic effect is produced, but the ability to cause receptor endocytosis is lost due to weak phosphorylation agonism
Solution Approach 1:
The patent creates composite molecular structures combining the aza spiro core framework with various aromatic substituents and side chain modifications. This composite design achieves optimal balance between MOR receptor activation potency and signaling pathway selectivity, producing ligands that effectively activate analgesic responses through G protein coupling while avoiding harmful β-arrestin-mediated effects
Data Source
AI summary
The present invention relates to an oxa spiro derivative, a preparation method therefor, and applications thereof in medicines. Particularly, the present invention relates to an oxa spiro derivative represented by formula (I), a preparation method therefor, and a pharmaceutical composition comprising the derivative, applications thereof as an MOR receptor agonist, and applications in the preparation of drugs for treating and/or preventing pains and pains-related diseases. Substituent groups in the formula (I) are same as definitions in the specification.